<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157778</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/33</org_study_id>
    <nct_id>NCT03157778</nct_id>
  </id_info>
  <brief_title>Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men</brief_title>
  <acronym>CannaPREG</acronym>
  <official_title>Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions&#xD;
      and over a meal in obese and normal-weight men subjects, to research a dysfunction in the&#xD;
      negative feed-back between pregnenolone and CB1 ligand in obese subjects. This dysfunction&#xD;
      could participate to the hyperactivity of endocannabinoid system saw in obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endocannabinoid system is an orexigenic key system, controlling the energy balance. It is&#xD;
      composed of receptors (ex: CB1), of endogenous ligands, the endocannabinoids (ex: anandamide&#xD;
      and 2- arachidonoylglycerol) and of enzymes implied in the synthesis and the degradation of&#xD;
      the endocannabinoids. Researches resulting from our group highlighted anomalies of the&#xD;
      plasmatic concentrations of endocannabinoid, in obese subject compared to normal-weight&#xD;
      subject. Those being higher in obese subject with a flatness of post prandial reduction of&#xD;
      AEA, so maintenance of elevated levels which can facilitate the food catch and create a&#xD;
      metabolic vicious circle. In addition, prestigious research resulting from our collaborators&#xD;
      highlighted in the animal that exposure to tetrahydrocannabinol (THC, ligand exogenic of CB1)&#xD;
      induced the synthesis of pregnenolone (neurosteroid) which, by an autocrine effect on the&#xD;
      CB1, inhibited the effects of the THC. In particular one of the principal behavioural&#xD;
      effects: the food intake.&#xD;
&#xD;
      We want to measure pregnenolone and endocannabinoid concentrations in men blood samples, to&#xD;
      observe if this association exists in fasting conditions and over a meal in normal-weight and&#xD;
      obese subjects. Obese subjects will be recruited during an hospitalization, while normal&#xD;
      subject will be recruited by a poster at Bordeaux university and Haut-Leveque hospital. They&#xD;
      will be included at Haut-Leveque hospital during morning at hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Actual">November 2, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Obese men versus normal-weight men</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pregnenolon plasmatic concentration in both groups.</measure>
    <time_frame>Change from 1 hour before lunch to 1 hour after lunch at inclusion day</time_frame>
    <description>Pregnenolon plasmatic concentration will be measured at several points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of neurosteroid plasma concentrations and endocannabinoid plasma concentrations</measure>
    <time_frame>Change from 1 hour before lunch to 1 hour after lunch at inclusion day</time_frame>
    <description>Neurosteroid and endocannabinoid plasma concentrations will be measured at several points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of endocannabinoid plasma concentration and pregnenolone plasma concentration</measure>
    <time_frame>Change from 1 hour before lunch to 1 hour after lunch at inclusion day</time_frame>
    <description>Endocannabinoid and pregnenolone concentrations will be measured at several points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal-weight men</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Obese men</intervention_name>
    <description>Biological measures before, just before, and after lunch, in obese men</description>
    <arm_group_label>Obese men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal-weight men</intervention_name>
    <description>Biological measures before, just before, and after lunch, in normal-weight men.</description>
    <arm_group_label>Normal-weight men</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese subjects:&#xD;
&#xD;
               -  men,&#xD;
&#xD;
               -  aged between 18 and 65 years,&#xD;
&#xD;
               -  BMI&gt;30kg/m2.&#xD;
&#xD;
          -  Normal-weight subjects:&#xD;
&#xD;
               -  men,&#xD;
&#xD;
               -  aged between 18 and 65 years,&#xD;
&#xD;
               -  BMI&lt;25kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For all subjects:&#xD;
&#xD;
               -  cannabis detected by urinary tetrahydrocannabinol presence,&#xD;
&#xD;
               -  treatment which can interfere with endocannabinoid system (antidepressant,&#xD;
                  antipsychotics, anxiolytics).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lhomme Edouard, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>USMR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregnenolone</keyword>
  <keyword>endocannabinoid</keyword>
  <keyword>food intake</keyword>
  <keyword>type-1 cannabinoid receptor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

